Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CapForce Inc.OPGN · Entity 9776 | Director | May 17, 2021 | May 19, 2021 |
| STANDARD BIOTOOLS INC.FLDM · Entity 6116 | Director | July 31, 2017 | August 03, 2017 |
| VERACYTE, INC.VCYT · Entity 2018 | Director | June 11, 2026 | June 15, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CapForce Inc.
Report date May 17, 2021 · Filed May 19, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 22,617 |
Reported balance
After 2021-05-17 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2021-05-17 · Exercise / conversion · Acquired 883 · Balance 22,617 F1: All stock information is adjusted to reflect a twenty-five-to-one reverse stock split effected on August 29, 2019. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 884 |
Reported balance
After 2021-05-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-05-17 · Exercise / conversion · Disposed 883 · Balance 884 F1: All stock information is adjusted to reflect a twenty-five-to-one reverse stock split effected on August 29, 2019. F2: Represents vesting of restricted stock units ("RSUs") granted in May 2019 that convert into common stock on a one-for-one basis. F3: On May 17, 2019, the Reporting Person was granted 2,650 RSUs (on a post-stock split basis). The RSUs were granted subject to forfeiture, which forfeiture restrictions will lapse as to one-third of the award on the first, second and third anniversaries of the date of grant, subject to acceleration as set forth in the Reporting Person's employment agreement with the Registrant. |
Filing footnotes · ownership attribution and instrument terms
F1: All stock information is adjusted to reflect a twenty-five-to-one reverse stock split effected on August 29, 2019.
F2: Represents vesting of restricted stock units ("RSUs") granted in May 2019 that convert into common stock on a one-for-one basis.
F3: On May 17, 2019, the Reporting Person was granted 2,650 RSUs (on a post-stock split basis). The RSUs were granted subject to forfeiture, which forfeiture restrictions will lapse as to one-third of the award on the first, second and third anniversaries of the date of grant, subject to acceleration as set forth in the Reporting Person's employment agreement with the Registrant.
STANDARD BIOTOOLS INC.
Report date July 31, 2017 · Filed August 03, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy jVen Capital, LLC | 58,551 |
Reported balance
After 2017-07-31 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2017-07-31 · Exercise / conversion · Acquired 5,000 · Balance 58,551 F1: The reporting person is managing member of jVen Capital, LLC. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Expires 2017-07-31 | Direct | 0 |
Reported balance
After 2017-07-31 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-07-31 · Exercise / conversion · Disposed 5,000 · Balance 0 F2: Each Restricted Stock Unit represents the contingent right to receive one share of FLDM common stock upon vesting of the unit. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person is managing member of jVen Capital, LLC.
F2: Each Restricted Stock Unit represents the contingent right to receive one share of FLDM common stock upon vesting of the unit.
VERACYTE, INC.
Report date June 11, 2026 · Filed June 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 34,634 |
Reported balance
After 2026-06-11 transaction · row 1
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 5,272 · Balance 34,634 F1: Restricted stock units awarded on June 11, 2026 vest in full on the first anniversary of the date of the grant or immediately prior to the Company's next annual meeting of stockholders, if earlier. In addition, the restricted stock units vest in full in the event of a change in control of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units awarded on June 11, 2026 vest in full on the first anniversary of the date of the grant or immediately prior to the Company's next annual meeting of stockholders, if earlier. In addition, the restricted stock units vest in full in the event of a change in control of the Issuer.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Foundation Medicine, Inc.
Report date July 31, 2018 · Filed August 02, 2018
Section 16 reporting ended · disclosed 2018-08-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-07-31 transaction · row 1
1 source rowRow 1 · 2018-07-31 · Other · Disposed 17,652 · Balance 0 F1: Foundation Medicine, Inc., a Delaware corporation (the "Company") entered into an Agreement and Plan of Merger, dated as of June 18, 2018, as amended (the "Merger Agreement"), with Roche Holdings, Inc., a Delaware corporation ("Parent" or "Roche"), and 062018 Merger Subsidiary, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Parent caused Merger Sub to conduct a tender offer (the "Tender Offer") for all of the issued and outstanding shares of common stock, par value $0.0001 per share, of the Company, at a price of $137 per share. On July 31, 2018, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn. On July 31, 2018, following consummation of the Tender Offer, Merger Sub merged with and into the Company. F2: The amount reported represents the number of shares sold by the reporting person in connection with the Tender Offer by Roche. |
| Common StockSEC Table I · non-derivative | Indirectby jVen Capital LLC | 0 |
Reported balance
After 2018-07-31 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2018-07-31 · Other · Disposed 9,300 · Balance 0 F1: Foundation Medicine, Inc., a Delaware corporation (the "Company") entered into an Agreement and Plan of Merger, dated as of June 18, 2018, as amended (the "Merger Agreement"), with Roche Holdings, Inc., a Delaware corporation ("Parent" or "Roche"), and 062018 Merger Subsidiary, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Parent caused Merger Sub to conduct a tender offer (the "Tender Offer") for all of the issued and outstanding shares of common stock, par value $0.0001 per share, of the Company, at a price of $137 per share. On July 31, 2018, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn. On July 31, 2018, following consummation of the Tender Offer, Merger Sub merged with and into the Company. F3: The amount reported represents the number of shares sold by the reporting person in connection with the tender offer for shares of Common Stock of the Issuer (the "Tender Offer") by Roche Holdings, Inc. ("Roche"). |
| stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.16 · Expires 2023-03-07 | Direct | 0 |
Reported balance
After 2018-07-31 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-07-31 · Other · Disposed 6,252 · Balance 0 F1: Foundation Medicine, Inc., a Delaware corporation (the "Company") entered into an Agreement and Plan of Merger, dated as of June 18, 2018, as amended (the "Merger Agreement"), with Roche Holdings, Inc., a Delaware corporation ("Parent" or "Roche"), and 062018 Merger Subsidiary, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Parent caused Merger Sub to conduct a tender offer (the "Tender Offer") for all of the issued and outstanding shares of common stock, par value $0.0001 per share, of the Company, at a price of $137 per share. On July 31, 2018, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn. On July 31, 2018, following consummation of the Tender Offer, Merger Sub merged with and into the Company. F4: This option was granted on March 7, 2013 and vested in sixteen equal quarterly installments thereafter, ending on January 10, 2017. |
| stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.21 · Expires 2024-06-18 | Direct | 0 |
Reported balance
After 2018-07-31 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2018-07-31 · Other · Disposed 13,385 · Balance 0 F1: Foundation Medicine, Inc., a Delaware corporation (the "Company") entered into an Agreement and Plan of Merger, dated as of June 18, 2018, as amended (the "Merger Agreement"), with Roche Holdings, Inc., a Delaware corporation ("Parent" or "Roche"), and 062018 Merger Subsidiary, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Parent caused Merger Sub to conduct a tender offer (the "Tender Offer") for all of the issued and outstanding shares of common stock, par value $0.0001 per share, of the Company, at a price of $137 per share. On July 31, 2018, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn. On July 31, 2018, following consummation of the Tender Offer, Merger Sub merged with and into the Company. |
| stock option (right to buySEC Table II · derivative / convertible security · Conversion / exercise price $7.12 · Expires 2023-05-22 | Direct | 0 |
Reported balance
After 2018-07-31 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2018-07-31 · Other · Disposed 4,922 · Balance 0 F1: Foundation Medicine, Inc., a Delaware corporation (the "Company") entered into an Agreement and Plan of Merger, dated as of June 18, 2018, as amended (the "Merger Agreement"), with Roche Holdings, Inc., a Delaware corporation ("Parent" or "Roche"), and 062018 Merger Subsidiary, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Parent caused Merger Sub to conduct a tender offer (the "Tender Offer") for all of the issued and outstanding shares of common stock, par value $0.0001 per share, of the Company, at a price of $137 per share. On July 31, 2018, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn. On July 31, 2018, following consummation of the Tender Offer, Merger Sub merged with and into the Company. F5: This stock option was granted on May 22, 2013 and vested in sixteen equal quarterly installments thereafter, ending on May 22, 2017. |
Filing footnotes · ownership attribution and instrument terms
F1: Foundation Medicine, Inc., a Delaware corporation (the "Company") entered into an Agreement and Plan of Merger, dated as of June 18, 2018, as amended (the "Merger Agreement"), with Roche Holdings, Inc., a Delaware corporation ("Parent" or "Roche"), and 062018 Merger Subsidiary, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Parent caused Merger Sub to conduct a tender offer (the "Tender Offer") for all of the issued and outstanding shares of common stock, par value $0.0001 per share, of the Company, at a price of $137 per share. On July 31, 2018, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn. On July 31, 2018, following consummation of the Tender Offer, Merger Sub merged with and into the Company.
F2: The amount reported represents the number of shares sold by the reporting person in connection with the Tender Offer by Roche.
F3: The amount reported represents the number of shares sold by the reporting person in connection with the tender offer for shares of Common Stock of the Issuer (the "Tender Offer") by Roche Holdings, Inc. ("Roche").
F4: This option was granted on March 7, 2013 and vested in sixteen equal quarterly installments thereafter, ending on January 10, 2017.
F5: This stock option was granted on May 22, 2013 and vested in sixteen equal quarterly installments thereafter, ending on May 22, 2017.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 25, 2017 Filed Aug 29, 2017 20:07 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 20,000 | $7.81 | $156,200.00 |
DisclosureSEC source: 0001384101-17-000056 · wf-form4_150403726119951.xml · nonDerivative · entry 1 JONES EVAN/ FA · CIK 0001020741 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by jVen Capital, LLC Disclosed balance after: 282,153 F1 · price: Represents weighted average sales price. Actual sale prices ranged from $7.75 to $7.91. F2 · price: Reporting Person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a security holder of the issuer detailed information regarding the price and number of shares sold within the range indicated. F3 · ownership.nature: The Reporting Person is the sole managing member of jVen Capital, LLC. Read SEC document |
| August 24, 2017 Filed Aug 25, 2017 20:16 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 20,000 | $7.83 | $156,600.00 |
DisclosureSEC source: 0001384101-17-000054 · wf-form4_150369214685902.xml · nonDerivative · entry 4 JONES EVAN/ FA · CIK 0001020741 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by jVen Capital, LLC Disclosed balance after: 302,153 F3 · price: Reporting Person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a security holder of the issuer detailed information regarding the price and number of shares sold within the range indicated. F4 · price: Represents weighted average sales price. Actual sale prices ranged from $7.75 to $8.01. F1 · ownership.nature: The Reporting Person is the sole managing member of jVen Capital, LLC. Read SEC document |
| August 23, 2017 Filed Aug 25, 2017 20:16 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 20,000 | $7.92 | $158,400.00 |
DisclosureSEC source: 0001384101-17-000054 · wf-form4_150369214685902.xml · nonDerivative · entry 3 JONES EVAN/ FA · CIK 0001020741 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by jVen Capital, LLC Disclosed balance after: 322,153 F2 · price: Represents weighted average sales price. Actual sale prices ranged from $7.89 to $8.01. F3 · price: Reporting Person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a security holder of the issuer detailed information regarding the price and number of shares sold within the range indicated. F1 · ownership.nature: The Reporting Person is the sole managing member of jVen Capital, LLC. Read SEC document |
| July 31, 2017 Filed Aug 3, 2017 00:34 UTC | STANDARD BIOTOOLS INC. FLDM · Entity 6116 | Exercise / conversionRestricted Stock Units · Derivative | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001162194-17-000085 · wf-form4_150172046490268.xml · derivative · entry 2 JONES EVAN/ FA · CIK 0001020741 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2017-07-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of FLDM common stock upon vesting of the unit. Read SEC document |
| July 31, 2017 Filed Aug 3, 2017 00:34 UTC | STANDARD BIOTOOLS INC. FLDM · Entity 6116 | Exercise / conversionCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001162194-17-000085 · wf-form4_150172046490268.xml · nonDerivative · entry 1 JONES EVAN/ FA · CIK 0001020741 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By jVen Capital, LLC Disclosed balance after: 58,551 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.nature: The reporting person is managing member of jVen Capital, LLC. Read SEC document |
| July 18, 2017 Filed Jul 18, 2017 20:22 UTC | CapForce Inc. OPGN · Entity 9776 | PurchaseWarrants to purchase Common Stock · Derivative | 1,875,000 | $0.00 Strike: $0.43 | $0.00 |
DisclosureSEC source: 0001140361-17-028093 · doc1.xml · derivative · entry 2 jVen Capital, LLC · CIK 0001641611 · Director · Chairman and CEO · 10% owner JONES EVAN/ FA · CIK 0001020741 · Chief Executive Officer Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,875,000 Underlying: Common Stock · 1,875,000 shares Expires 2022-07-18 F1 · ownership.direct: Evan Jones, the Chairman of the Board and the Chief Executive Officer of OpGen, Inc. (the "Company"), is the managing member of jVen Capital, LLC and is the indirect beneficial owner of all shares of the Company's Common Stock and warrants to purchase Common Stock owned by jVen Capital, LLC. Read SEC document |
| July 18, 2017 Filed Jul 18, 2017 20:22 UTC | CapForce Inc. OPGN · Entity 9776 | PurchaseCommon Stock | 1,875,000 | $0.40 | $750,000.00 |
DisclosureSEC source: 0001140361-17-028093 · doc1.xml · nonDerivative · entry 1 jVen Capital, LLC · CIK 0001641611 · Director · Chairman and CEO · 10% owner JONES EVAN/ FA · CIK 0001020741 · Chief Executive Officer Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,680,604 F1 · ownership.direct: Evan Jones, the Chairman of the Board and the Chief Executive Officer of OpGen, Inc. (the "Company"), is the managing member of jVen Capital, LLC and is the indirect beneficial owner of all shares of the Company's Common Stock and warrants to purchase Common Stock owned by jVen Capital, LLC. Read SEC document |
| July 05, 2017 Filed Jul 10, 2017 23:53 UTC | CapForce Inc. OPGN · Entity 9776 | PurchaseWarrants to purchase Common Stock · Derivative | 158,730 | $0.00 Strike: $0.78 | $0.00 |
DisclosureSEC source: 0001140361-17-027562 · doc1.xml · derivative · entry 1 jVen Capital, LLC · CIK 0001641611 · Director · Chairman and CEO · 10% owner JONES EVAN/ FA · CIK 0001020741 · Chief Executive Officer Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,730 Underlying: Common Stock · 158,730 shares Expires 2023-07-05 F1 · security: Issuance of warrants pursuant to that certain Amended & Restated Note Purchase Agreement dated July 10, 2017. F2 · ownership.direct: Evan Jones, the Chairman of the Board and the Chief Executive Officer of OpGen, Inc. (the "Company"), is the managing member of jVen Capital, LLC and is the indirect beneficial owner of all shares of the Company's Common Stock owned by jVen Capital, LLC. Read SEC document |
| July 05, 2017 Filed Jul 25, 2017 21:53 UTC Amendment | CapForce Inc. OPGN · Entity 9776 | PurchaseWarrants to purchase Common Stock · Derivative | 158,730 | $0.00 Strike: $0.69 | $0.00 |
DisclosureSEC source: 0001140361-17-028657 · doc1.xml · derivative · entry 1 jVen Capital, LLC · CIK 0001641611 · Director · Chairman and CEO · 10% owner JONES EVAN/ FA · CIK 0001020741 · Chief Executive Officer Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,730 Underlying: Common Stock · 158,730 shares Expires 2022-07-05 F1 · security: Issuance of warrants pursuant to that certain Amended & Restated Note Purchase Agreement dated July 10, 2017. F2 · derivative.exercise_price: The purpose of this Form 4/A is to correct the exercise price and expiration date for this warrant issuance. F2 · derivative.expiration_date: The purpose of this Form 4/A is to correct the exercise price and expiration date for this warrant issuance. F3 · ownership.direct: Evan Jones, the Chairman of the Board and the Chief Executive Officer of OpGen, Inc. (the "Company"), is the managing member of jVen Capital, LLC and is the indirect beneficial owner of all shares of the Company's Common Stock owned by jVen Capital, LLC. Read SEC document |
| June 28, 2017 Filed Jul 6, 2017 20:38 UTC | CapForce Inc. OPGN · Entity 9776 | PurchaseWarrants to purchase Common Stock · Derivative | 70,423 | $0.00 Strike: $0.78 | $0.00 |
DisclosureSEC source: 0001140361-17-027360 · doc1.xml · derivative · entry 1 jVen Capital, LLC · CIK 0001641611 · Director · Chairman and CEO · 10% owner JONES EVAN/ FA · CIK 0001020741 · Chief Executive Officer Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,423 Underlying: Common Stock · 70,423 shares Expires 2022-06-28 F1 · security: Issuance of warrants pursuant to that certain Note Purchase Agreement dated May 31, 2017. F2 · ownership.direct: Evan Jones, the Chairman of the Board and the Chief Executive Officer of OpGen, Inc. (the "Company"), is the managing member of jVen Capital, LLC and is the indirect beneficial owner of all shares of the Company's Common Stock and derivative securities owned by jVen Capital, LLC. Read SEC document |
| June 28, 2017 Filed Jul 10, 2017 23:44 UTC Amendment | CapForce Inc. OPGN · Entity 9776 | PurchaseWarrants to purchase Common Stock · Derivative | 149,788 | $0.00 Strike: $0.78 | $0.00 |
DisclosureSEC source: 0001140361-17-027561 · doc1.xml · derivative · entry 1 jVen Capital, LLC · CIK 0001641611 · Director · Chairman and CEO · 10% owner JONES EVAN/ FA · CIK 0001020741 · Chief Executive Officer Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,788 Underlying: Common Stock · 149,788 shares Expires 2022-06-28 F1 · security: The purpose of this Form 4/A is to report an increase in the number of Warrants to purchase Common Stock issued to jVen Capital, LLC pursuant to an amendment and restatement of that certain Note Purchase Agreement dated May 31, 2017. F2 · security: Issuance of warrants pursuant to that certain amended and restated Note Purchase Agreement dated July 10, 2017. F3 · ownership.direct: Evan Jones, the Chairman of the Board and the Chief Executive Officer of OpGen, Inc. (the "Company"), is the managing member of jVen Capital, LLC and is the indirect beneficial owner of all shares of the Company's Common Stock owned by jVen Capital, LLC. Read SEC document |
| June 28, 2017 Filed Jul 25, 2017 21:51 UTC Amendment | CapForce Inc. OPGN · Entity 9776 | PurchaseWarrants to purchase Common Stock · Derivative | 140,845 | $0.00 Strike: $0.78 | $0.00 |
DisclosureSEC source: 0001140361-17-028656 · doc1.xml · derivative · entry 1 jVen Capital, LLC · CIK 0001641611 · Director · Chairman and CEO · 10% owner JONES EVAN/ FA · CIK 0001020741 · Chief Executive Officer Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,845 Underlying: Common Stock · 140,845 shares Expires 2022-06-28 F1 · security: The purpose of this Form 4/A is to report the correct increase in the number of Warrants to purchase Common Stock issued to jVen Capital, LLC pursuant to an amendment and restatement of that certain Note Purchase Agreement dated May 31, 2017. F2 · security: Issuance of warrants pursuant to that certain amended and restated Note Purchase Agreement dated July 10, 2017. F3 · ownership.direct: Evan Jones, the Chairman of the Board and the Chief Executive Officer of OpGen, Inc. (the "Company"), is the managing member of jVen Capital, LLC and is the indirect beneficial owner of all shares of the Company's Common Stock owned by jVen Capital, LLC. Read SEC document |
| June 20, 2017 Filed Jun 22, 2017 20:06 UTC | Foundation Medicine, Inc. FMI · Entity 164565 | GrantCommon Stock | 5,786 | $40.05 | $231,729.30 |
DisclosureSEC source: 0001209191-17-041331 · doc4.xml · nonDerivative · entry 1 JONES EVAN/ FA · CIK 0001020741 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,552 F1 · shares: Represents restricted stock units granted by the Issuer pursuant to its 2013 Stock Option and Incentive Plan and the Issuer's Non-Employee Director Compensation Policy. The restricted stock units vest on the earlier of June 20, 2018 or the Issuer's next annual meeting of stockholders, subject to the director's continued service on the Board of Directors, or immediately upon the death or disability of the director or upon a change-of-control of the Issuer. Read SEC document |
| June 07, 2017 Filed Jun 7, 2017 21:20 UTC | VERACYTE, INC. VCYT · Entity 2018 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $7.94 | $0.00 |
DisclosureSEC source: 0001384101-17-000038 · wf-form4_149687041569930.xml · derivative · entry 1 JONES EVAN/ FA · CIK 0001020741 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2027-06-07 F1 · derivative.exercise_date: The option becomes exercisable in full on the first anniversary of the date of the grant or immediately prior to the Company's next annual meeting of stockholders, if earlier. In addition, the option vests in full in the event of a change in control of the Company. Read SEC document |
| June 07, 2017 Filed Jun 8, 2017 23:31 UTC | STANDARD BIOTOOLS INC. FLDM · Entity 6116 | SaleCommon Stock | 1,400 | $4.41 | $6,167.00 |
DisclosureSEC source: 0001162194-17-000065 · wf-form4_149696467750655.xml · nonDerivative · entry 2 JONES EVAN/ FA · CIK 0001020741 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By jVen Capital, LLC Disclosed balance after: 53,551 F1 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. The June 6 shares were sold in multiple transactions at prices ranging from $4.50 to $4.59, inclusive, and the June 7 shares were sold in multiple transactions at prices ranging from $4.40 to $4.41, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. F2 · ownership.nature: The reporting person is managing member of jVen Capital, LLC. Read SEC document |
| June 07, 2017 Filed Aug 25, 2017 20:16 UTC | VERACYTE, INC. VCYT · Entity 2018 | GiftCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001384101-17-000054 · wf-form4_150369214685902.xml · nonDerivative · entry 2 JONES EVAN/ FA · CIK 0001020741 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by jVen Capital, LLC Disclosed balance after: 342,153 F1 · ownership.nature: The Reporting Person is the sole managing member of jVen Capital, LLC. Read SEC document |
| June 07, 2017 Filed Aug 25, 2017 20:16 UTC | VERACYTE, INC. VCYT · Entity 2018 | GiftCommon Stock | 3,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001384101-17-000054 · wf-form4_150369214685902.xml · nonDerivative · entry 1 JONES EVAN/ FA · CIK 0001020741 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by jVen Capital, LLC Disclosed balance after: 345,153 F1 · ownership.nature: The Reporting Person is the sole managing member of jVen Capital, LLC. Read SEC document |
| June 06, 2017 Filed Jun 8, 2017 23:31 UTC | STANDARD BIOTOOLS INC. FLDM · Entity 6116 | SaleCommon Stock | 9,500 | $4.56 | $43,343.75 |
DisclosureSEC source: 0001162194-17-000065 · wf-form4_149696467750655.xml · nonDerivative · entry 1 JONES EVAN/ FA · CIK 0001020741 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By jVen Capital, LLC Disclosed balance after: 54,951 F1 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. The June 6 shares were sold in multiple transactions at prices ranging from $4.50 to $4.59, inclusive, and the June 7 shares were sold in multiple transactions at prices ranging from $4.40 to $4.41, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. F2 · ownership.nature: The reporting person is managing member of jVen Capital, LLC. Read SEC document |
| February 23, 2017 Filed Feb 27, 2017 22:13 UTC | CapForce Inc. OPGN · Entity 9776 | GrantStock Option Award · Derivative | 80,000 | $0.00 Strike: $1.03 | $0.00 |
DisclosureSEC source: 0001140361-17-009454 · doc1.xml · derivative · entry 1 JONES EVAN/ FA · CIK 0001020741 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2027-02-23 F1 · derivative.exercise_date: The option vests 25% on February 23, 2018 and 6.25% quarterly thereafter on the first business day of each quarter for a period of three years. Read SEC document |
| December 09, 2016 Filed Feb 13, 2017 21:42 UTC | VERACYTE, INC. VCYT · Entity 2018 | GiftCommon Stock | 14,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001384101-17-000003 · wf-form5_148702211658860.xml · nonDerivative · entry 2 JONES EVAN/ FA · CIK 0001020741 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by jVen Capital, LLC Disclosed balance after: 348,753 F1 · ownership.nature: The Reporting Person is the sole managing member of jVen Capital, LLC. Read SEC document |
| December 08, 2016 Filed Feb 13, 2017 21:42 UTC | VERACYTE, INC. VCYT · Entity 2018 | GiftCommon Stock | 8,050 | $0.00 | $0.00 |
DisclosureSEC source: 0001384101-17-000003 · wf-form5_148702211658860.xml · nonDerivative · entry 1 JONES EVAN/ FA · CIK 0001020741 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by jVen Capital, LLC Disclosed balance after: 363,553 F1 · ownership.nature: The Reporting Person is the sole managing member of jVen Capital, LLC. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.